Clinical Research Trials

Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.

Y-HEP Health Center | Jonathan Lax Health Center


The following clinical trials are ongoing at the Lax Center and currently enrolling patients:

WINCORE

Description: A longitudinal, observational study evaluating immune outcomes of COVID-19 vaccination in at risk populations


VAMOS

Trial Number: TH9507-CTR-1030

Description: The Visceral Adiposity and Measurements Observational Study


A Randomized, Open-Label Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir for HIV Treatment

Trial Number: GS-US-563-6041

Description: A Phase 2 Randomized, Open‑Label, Active‑Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV


Studies of the Immunopathogenesis of Chronic and Emerging Viral Infections

Description: Sponsored by The Wistar Institute


The following clinical trials are ongoing at the Lax Center but are NOT enrolling new patients:

DEFINE

Trial Number: TMC114FD2HTX4004

Description: Symtuza (D/C/F/TAF) Single Tablet Regimen (STR) Evaluated as an STR in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain


The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:

Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir (LEN) for HIV Pre-Exposure Prophylaxis (PrEP)

Trial Number: GS-US-528-9023

Description: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection


Acceptability of Long-Acting Injectable Lenacapavir (LEN) Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for HIV Pre-Exposure Prophylaxis (PrEP): Qualitative Insights Into Social and Behavioral Contexts

Trial Number: GS-US-528-6364

Description: A Qualitative Study for participants already enrolled in GS-US-528-9023 to examine Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People


PennE

Description: Supporting PrEP Initiation and Mental Health Screening in Community Care Settings with Automated, Proactive Text-Messaging


For more information on any of the clinical trials listed, please contact the Research Department at 215-344-1631.